Key Points
- Executive sale: EVP Paul Mahon sold 8,300 United Therapeutics shares at an average price of $523.14, generating approximately $4.34 million. His remaining direct holdings fell 15.52% to 45,172 shares.
- Financial performance: United Therapeutics reported quarterly EPS of $7.27, beating estimates of $6.86, while revenue of $783.3 million missed expectations and declined 1.9% year over year.
- Market outlook: Shares opened at $513.12, and analysts maintain a “Moderate Buy” consensus with an average price target of $646. Institutional investors own approximately 94.08% of the company.
United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) EVP Paul Mahon sold 8,300 shares of United Therapeutics stock in a transaction on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total transaction of $4,342,062.00. Following the completion of the sale, the executive vice president directly owned 45,172 shares in the company, valued at $23,631,280.08. This represents a 15.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
United Therapeutics Stock Down 1.5%
UTHR opened at $513.12 on Friday. The firm's fifty day simple moving average is $533.08 and its two-hundred day simple moving average is $537.36. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35. The company has a market cap of $22.01 billion, a price-to-earnings ratio of 18.36, a PEG ratio of 1.76 and a beta of 0.59.
United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping analysts' consensus estimates of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analysts' expectations of $804.65 million. United Therapeutics had a net margin of 41.56% and a return on equity of 20.18%. The company's quarterly revenue was down 1.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $6.41 earnings per share. On average, research analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current year.
Analysts Set New Price Targets
Several brokerages have recently weighed in on UTHR. Royal Bank Of Canada lowered their target price on United Therapeutics from $704.00 to $677.00 and set an "outperform" rating on the stock in a report on Thursday, August 6th. Bank of America reduced their price target on shares of United Therapeutics from $620.00 to $613.00 and set a "neutral" rating on the stock in a research report on Friday, July 10th. TD Cowen reissued a "buy" rating on shares of United Therapeutics in a research note on Thursday, May 21st. JPMorgan Chase & Co. increased their price target on United Therapeutics from $685.00 to $687.00 and gave the stock an "overweight" rating in a report on Thursday, July 23rd. Finally, Weiss Ratings raised United Therapeutics from a "buy (b-)" rating to a "buy (b)" rating in a research report on Thursday, August 13th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, United Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $646.00.
View Our Latest Stock Analysis on United Therapeutics
Hedge Funds Weigh In On United Therapeutics
Several institutional investors have recently modified their holdings of the business. Geneos Wealth Management Inc. grew its stake in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock worth $45,000 after purchasing an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its position in shares of United Therapeutics by 18.8% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company's stock worth $127,000 after buying an additional 70 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of United Therapeutics during the second quarter worth approximately $277,000. Cerity Partners LLC lifted its stake in United Therapeutics by 77.3% in the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company's stock worth $3,691,000 after acquiring an additional 5,600 shares during the last quarter. Finally, Bank of Nova Scotia raised its holdings in shares of United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company's stock valued at $468,000 after purchasing an additional 105 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company's stock.
About United Therapeutics
(
Get Free Report)
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company's primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
